SCHEMBL3627239

SCHEMBL3627239

C=Cc1ccc(OC)cc1OC

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 15/20 0.70
CYP1A1 P04798 14/20 0.70
CYP1B1 Q16678 14/20 0.70
ALDH1A1 P00352 3/20 0.66
NFE2L2 Q16236 2/20 0.61
CYP3A4 P08684 2/20 0.58
CYP2C19 P33261 2/20 0.58
MEN1 O00255 2/20 0.58
MAPT P10636 2/20 0.58
KMT2A Q03164 2/20 0.58
CYP2E1 P05181 1/20 0.58
CYP2C8 P10632 1/20 0.58
CYP2D6 P10635 1/20 0.58
CYP2A6 P11509 1/20 0.58
CYP2C9 P11712 1/20 0.58
CYP4B1 P13584 1/20 0.58
CYP2B6 P20813 1/20 0.58
CYP3A5 P20815 1/20 0.58
CYP2A7 P20853 1/20 0.58
CYP3A7 P24462 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30411244 1.00 CYP1A2 (0.70) CYP1A2CYP1A1CYP1B1ALDH1A1NFE2L2
SCHEMBL5026272 0.83 CYP1A2 (0.50) CYP1A2CYP1A1CYP1B1ALDH1A1NFE2L2
SCHEMBL1415874 0.83 CYP1A2 (0.50) CYP1A2CYP1A1CYP1B1ALDH1A1NFE2L2
SCHEMBL28347627 0.83 CYP1A1 (0.50) CYP1A2CYP1A1CYP1B1ALDH1A1NFE2L2
SCHEMBL1792533 0.83 CYP1A1 (0.61) CYP1A2CYP1A1CYP1B1ALDH1A1NFE2L2
SCHEMBL3785302 0.83 CYP1A2 (0.70) CYP1A2CYP1A1CYP1B1ALDH1A1NFE2L2
SCHEMBL25706432 0.83 CYP1A2 (1.00) CYP1A2CYP1A1CYP1B1ALDH1A1NFE2L2
SCHEMBL145083 0.83 CYP1A2 (0.76) CYP1A2CYP1A1CYP1B1ALDH1A1NFE2L2
SCHEMBL30567454 0.83 CYP1A2 (0.52) CYP1A2CYP1A1CYP1B1ALDH1A1NFE2L2
SCHEMBL9065566 0.83 CYP1A2 (0.52) CYP1A2CYP1A1CYP1B1ALDH1A1NFE2L2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112679642-B Cycloolefin copolymer and preparation method thereof 广东华锦达新材科技有限公司 2023-05-12 CN claimed
CN-112679642-A Cycloolefin copolymer and preparation method thereof 广东新华粤石化集团股份公司 2021-04-20 CN claimed
EP-3310844-A1 CROSS-LINKED UNSATURATED POLYCARBONATE RESINS UBE Corporation Europe, S.A.U. (ES) 2018-04-25 EP claimed
WO-2016202914-A1 CROSS-LINKED UNSATURATED POLYCARBONATE RESINS UBE CORPORATION EUROPE, S.A.U. (ES) 2016-12-22 WO claimed
EP-3106486-A1 CROSS-LINKED UNSATURATED POLYCARBONATE RESINS UBE Corporation Europe, S.A.U. (ES) 2016-12-21 EP claimed
CN-1184209-C Chuanxiong alkoxide derivative and its preparation and medicinal composition containing it and use thereof SHANGDOG UNIV (CN) 2005-01-12 CN claimed
EP-4707264-A2 COMPOUNDS AND THE USE THEREOF IN METATHESIS REACTIONS Verbio SE (DE) 2026-03-11 EP disclosed
US-20260062393-A1 Compounds CTXT PTY LTD (AU) 2026-03-05 US disclosed
EP-4680226-A2 ACYLSULFONAMIDE KAT6A INHIBITORS Olema Pharmaceuticals, Inc. (US) 2026-01-21 EP disclosed
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS INC (US) 2026-01-15 US disclosed
EP-4122924-B1 COMPOUNDS AND THE USE THEREOF IN METATHESIS REACTIONS VERBIO SE (DE) 2025-11-19 EP disclosed
US-12428379-B2 Acylsulfonamide KAT6A inhibitors OLEMA PHARMACEUTICALS, INC. (US) 2025-09-30 US disclosed
US-12365655-B2 Compounds CTXT PTY LTD (AU) 2025-07-22 US disclosed
US-5510434-A Catalyst for producing aromatic vinyl compound polymer and process for producing aromatic vinyl compound polymer by using same IDEMITSU KOSAN CO., LTD. (JP) 1996-04-23 US disclosed
EP-0691575-A2 Positive photosensitive composition FUJI PHOTO FILM CO., LTD. (JP) 1996-01-10 EP disclosed
EP-0655467-A1 Catalyst for producing aromatic vinyl compound polymer and process for producing aromatic vinyl compound polymer by using same IDEMITSU KOSAN COMPANY LIMITED (JP) 1995-05-31 EP disclosed
EP-0320742-B1 Process for the after-treatment of developed flexographic printing platens DU PONT (US) 1995-04-05 EP disclosed
EP-0320742-A2 Process for the after-treatment of developed flexographic printing platens E.I. DU PONT DE NEMOURS AND COMPANY (US) 1989-06-21 EP disclosed
US-4145490-A Carboxylated copolymers of isobutylene and a vinylbenzene E. I. DU PONT DE NEMOURS AND COMPANY (US) 1979-03-20 US disclosed
US-4031168-A ADHESIVES, FILMS E. I. DU PONT DE NEMOURS AND COMPANY (US) 1977-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12428379-B2 Acylsulfonamide KAT6A inhibitors KAT6A, KAT2A, KAT6B CYP1A2 3885/4885CYP1A1 3991/4885CYP1B1 3699/4885
US-20260062393-A1 Compounds SCN2B, ABCB11, SCN1B CYP1A2 383/4885CYP1A1 555/4885CYP1B1 239/4885
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS KAT6A, KAT2A, KAT6B CYP1A2 2880/4885CYP1A1 1611/4885CYP1B1 1245/4885
US-12365655-B2 Compounds SLC10A1, ABCB11, PCSK9 CYP1A2 97/4885CYP1A1 128/4885CYP1B1 93/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.